• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Digital therapeutics startup Neuroglee raises $10M to help people with neurodegenerative conditions

September 9, 2021 by David Barret Leave a Comment

Neuroglee Therapeutics, a startup developing digital therapeutics for people with neurodegenerative diseases, has raised a $10 million Series A led by Openspace Ventures and EDBI. The funding will be used to launch virtual neurology clinics and to support Neuroglee’s move to Boston. Other participants included Ramen Singh, the former chief executive officer of Mundipharma; Biofourmis co-founders Kuldeep Singh Rajput and Wendou Liu; and Eisai Co., the Japanese pharmaceutical that led Neuroglee’s last round last year.

In an email, founder and chief executive officer Aniket Singh Rajput told TechCrunch that the company is moving to Boston because the city “is one of the largest digital health hubs in the world. As a company devoted to developing our first line of solutions for treating mild cognitive impairment related to difficult-to-treat neurodegenerative conditions such as Alzheimer’s disease, we believe Boston will offer us the strategic support in order to do so.”

Neuroglee gets $2.3 million to develop digital therapeutics for neurodegenerative diseases

Neuroglee and the Mayo Clinic are currently working together on a new platform called Neuroglee Connect. Based on the Mayo Clinic’s 10-day in-person program HABIT (Health Action to Benefit Independence and Thinking) for people with mild cognitive impairment from possible neurodegenerative conditions, Neuroglee’s technology will enable HABIT to scale, making it available to patients and caregivers in their homes. Neuroglee Connect users will also have access to health navigators who are available 24 hours and clinical care teams for assessments and interventions.

Neuroglee’s product pipeline also includes digital therapeutics for Parkinson’s disease and strokes.

Since Neuroglee’s previous funding announcement in December 2020, Rajput said it has hit milestones like the successful product development of NG-001, its prescription digital therapy software for Alzheimer’s, and began work on its proof-of-concept study to earn NG-001 a Breakthrough Designation from the Federal Drug Administration.

Neuroglee’s adaptive learning tech uses machine learning and biomarkers related to cognitive function, mood and behavior to automatically personalize therapy plans for each patient, who access the software through a smartphone or tablet.

“For example, adjustments will be made to the number and type of tasks and games that are offered, based on the speed of the patient’s finger movements, time to complete games or tasks, and their facial expression identified through the device camera,” said Rajput. “The solution also incorporates reminiscence therapy, which uses images from the patient’s past to evoke positive memories and emotions, which have been shown to improve cognitive functioning.”

SoftBank Vision Fund 2 leads $100 million Series C in digital therapeutics company Biofourmis

Venture investing in elder tech

 

Source Link Digital therapeutics startup Neuroglee raises $10M to help people with neurodegenerative conditions

David Barret
David Barret

Related posts:

  1. Hackers are hiring more English speakers to write believable email scams
  2. JBL Quantum 350 looks like a great affordable wireless gaming headset
  3. Canada trade surplus narrowed in July to C$778 million
  4. Life insurers shift to pre-pandemic norms after COVID vaccine roll-outs

Filed Under: News

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

  • Get Ready, Skywatchers: A “Dazzling” Total Lunar Eclipse Is Coming In 2025
  • How A Man Won The Lottery 14 Times Using Unbelievably Basic Math
  • What Are The Amazon’s “Flying Rivers”? And Why Every Single One Of Us Relies On Them
  • Curious New Microbe With Tiny Genome Toes The Line Between Cell And Virus
  • We’ve Just Found Out Where The World’s Longest-Living Vertebrate Has Its Babies
  • For The First Time, An Animal Has Been Shown Responding To Plant-Produced Sounds
  • Deep Ocean Currents Have “Weather” And Seasonal Changes That We’re Only Just Learning About
  • Stratus: What Are The Symptoms Of The Latest COVID-19 Subvariant To Spread Around The World?
  • In 1927, Henry Ford Tried To Build A Town In The Amazon And Things Went Very, Very Badly
  • Human Botfly: Say Hello To The Parasite That Would Love To Get Under Your Skin
  • Is The Weather Making Your Headache Worse?
  • “Zoning Out” Actually Helps You Learn? Data From Up To 90,000 Brain Cells Says So
  • Over Past 250,000 Years, Three Major Waves Of Human-Neanderthal Interbreeding Have Been Identified
  • Zebrafish “Catch” Yawns Just Like Us – We Might Need To Rethink Evolution To Account For That
  • 80,000-Year-Old Neanderthal Footprints Reveal How Children Hunted On Beaches
  • 5 Animals That Have Absolutely No Business Jumping (In Our Very Humble, Definitely Unbiased Opinion)
  • Polar Vortex Patterns Explain Winter Cold Snaps Against Background Warming Trend
  • Scientists Tracked An Olm For 2,569 Days And It Did Not Move An Inch
  • Look Out For “Fireballs”: The Best Meteor Shower Of 2025 Is About To Commence, According To NASA
  • Why Do Many Large Language Models Give The Same Answer To This “Random” Number Query?
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version